

# ACT Accelerator Dx Partnership

Brief to Member States

16 July 2020

**#UnitedAgainstCoronavirus**

**#StrongerTogether | #GlobalResponse | #GlobalGoalUnite**



World Health  
Organization



**FIND**


Because diagnosis matters

 The Global Fund



“  
We have a simple  
message to all  
countries:  
**test, test, test.”**

# Why do we need diagnostics?




- Testing is essential at every stage of the pandemic response
- Effective diagnostics are essential to limit the spread of infection
- Many countries have shown that “test, trace and isolate” works

# How can testing help save lives now?

## By averting 1 death for every ~1000 tests

**Early, targeted testing helps to isolate cases, manage patients and prevent spread**



1. HCW: Health Care Workers Note: Test rate – tests per 1,000, at two weeks after the 100th confirmed case; Death rate – daily deaths per 1 million as of May 12, shown as a rolling seven-day average; Source: TIME Magazine (Emily Barone, Lon Tweeten, Elijah Wolfson - Our World in Data; FIND COVID-19 test tracker (June 2<sup>nd</sup> 2020)

# Barriers mean we cannot reach everyone who needs a test today

## **CURRENT TESTING STRATEGIES RELY ON SYSTEMS & INFRASTRUCTURE**

- Complex, expensive, slow, laboratory-based, resource-intensive

## **SUPPLY SHORTAGES JEOPARDIZE ACCESS**

- Manufacturing capacity is not in place to rapidly scale up production of tests to meet global demand

## **RAPID DIAGNOSTIC TESTS NEED INNOVATION**

- Need faster, more accurate, affordable, easier to use tests

**TESTING IN LMICs IS 10% OF WHAT IT IS IN HICS, <1% IN LICs**

# ACT-A Diagnostics Partnership

## DIAGNOSTICS PARTNERSHIP

FIND (co-convenor)

Global Fund (co-convenor)

### WHO

- Academia
- Industry
- Regulators
- CSOs
- Funders
- International organizations
- Country reps

## OUR GOAL

To drive universal and equitable access to diagnostics as per WHA resolution

## HOW WE ARE HELPING


R&D - Supporting R&D

Market Readiness - Engaging in market-shaping interventions to stimulate rapid, massive scale-up

Supply - Powering supply and distribution, with additional support for LMICs

Country Readiness - Building the capacity of countries' health infrastructures to enable uptake of the tests

# What do we want to deliver in next 12 months?



## R&D

Well-performing **Ag RDTs & point-of-care molecular tests** developed

Non-proprietary **test result reader app and interoperability solution** developed



## Market Readiness

Regionalized production incl. in LMICs & mechanism set up to make **RDTs affordable and available**



## Supply

**500m tests** procured



## Country Preparedness

Country **policies and uptake in integrated testing strategies** driven in 50+ countries

**10,000 health care workers** trained




All countries able to deploy **affordable, quality POC tests**

Significant number of LMICs have been supported to put in place **effective test, trace, isolate strategies**

Disruption of **core health services** minimized

# Meeting these milestones will require total of \$6B and closing existing funding gaps





# By closing the urgent funding gaps, Member States can benefit from...

Global investments in R&D and market interventions to create competitive markets that will make tests more accessible and affordable for all countries

Stronger country testing capacity and development of testing strategies

Support for selecting the best tests for local needs

Preventing the procurement of low quality or fake tests

Well-performing innovative tests brought to market

Ability to scale procurement of existing PCR and new RDT tests

Making informed decisions about pandemic control measures and when lockdowns can be eased, and economies re-opened

# What have we achieved in the past 8 weeks?

**1**

**Launched call to scale R&D and manufacturing Antigen RDTs**

**2**

**Set up multi-country evaluation platform to test diagnostics & completed 20+ evaluations**

**3**

**Developed Target Product Profiles to guide test development**

**4**

**Added 15 tests to WHO Emergency Use List**

**5**

**Modelled impact of diagnostics**

**6**

**Shared critical data with countries to inform decision-making**

**7**

**Procured 6m tests**


**8**

**Established ACT-A Dx Partnership working groups**



# Dx Consortium has already procured more than 6m tests

## Tests Ordered



# Key innovations underway to address point of care testing and scalability


**Manufacturing innovations**  
Advanced semi-conductor based microfluidics  
Scalable manufacturing for Low cost products

**Business model innovations**  
Local-manufacturing and improved distribution  
Enhanced connectivity for data transmission  
Link to payment /insurance services

**Technology breakthroughs**  
Improved reagents, e.g. new antibodies  
More sensitive readouts, e.g. new particles  
Next generation technologies- e.g. Crispr-based  
Enhanced digital integration

**Multi-modality capabilities**  
Multiplex different targets; e.g. Covid and Flu  
Platform approach: Integration of multiple platforms,  
Combined immuno- and molecular assays

**Innovations in usability**  
Instrument-free, handheld, portable systems  
Decentralized testing for pharmacy or at-home use




# Testing is vital to both mitigating direct impact of COVID-19 and minimizing knock-on impact

We risk facing future bottlenecks when it is time to roll out approved therapeutics and vaccines



+ Need for differential testing

And we will lose ground on global health gains over past 20 years



Source: Imperial College London. [www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-19-hiv-tb-malaria/](http://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-19-hiv-tb-malaria/) (accessed 3 June 2020)



## **In summary**

Over the next 12 months, we need \$6 billion to procure and deploy 500 million tests in countries that might otherwise miss out

The world must seize a window of opportunity and put in place the right conditions for large-scale testing strategies now

Every dollar invested in testing today is a dollar invested in our future global health security and an opportunity to protect the health advances of recent decades



**#UnitedAgainstCoronavirus**

**#StrongerTogether | #GlobalResponse | #GlobalGoalUnite**



World Health  
Organization



**FIND**

Because diagnosis matters

 **The Global Fund**